91 related articles for article (PubMed ID: 21785472)
1. Lack of efficacy of rituximab in refractory sclerodermatous chronic GVHD.
George L; George B; Gottlieb DJ; Hertzberg M; Fernandez-Peñas P
Bone Marrow Transplant; 2012 May; 47(5):737-8. PubMed ID: 21785472
[No Abstract] [Full Text] [Related]
2. Repeated course of rituximab for treatment of nephrotic syndrome in patients with chronic GVHD.
Mellon-Reppen S; Ratanatharathorn V; Cronin S; Uberti JP
Bone Marrow Transplant; 2010 Dec; 45(12):1758-9. PubMed ID: 20383208
[No Abstract] [Full Text] [Related]
3. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease.
Okamoto M; Okano A; Akamatsu S; Ashihara E; Inaba T; Takenaka H; Katoh N; Kishimoto S; Shimazaki C
Leukemia; 2006 Jan; 20(1):172-3. PubMed ID: 16239908
[No Abstract] [Full Text] [Related]
4. Safety and efficacy of rituximab in steroid-refractory chronic GVHD.
Clavert A; Chevallier P; Guillaume T; Delaunay J; Le Gouill S; Mahe B; Dubruille V; Gastinne T; Blin N; Moreau P; Mohty M
Bone Marrow Transplant; 2013 May; 48(5):734-6. PubMed ID: 23085828
[No Abstract] [Full Text] [Related]
5. Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion.
Voltarelli JC; Ahmed H; Paton EJ; Stracieri AB; Holman P; Bashey A; Coutinho M; Simoes BP; Ball ED; Carrier E
Bone Marrow Transplant; 2001 Jul; 28(1):97-9. PubMed ID: 11498752
[TBL] [Abstract][Full Text] [Related]
6. Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
Molés-Poveda P; Montesinos P; Sanz-Caballer J; de Unamuno B; Piñana JL; Sahuquillo A; Botella-Estrada R
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):241-247. PubMed ID: 29254596
[TBL] [Abstract][Full Text] [Related]
7. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
Moreno-Romero JA; Fernández-Avilés F; Carreras E; Rovira M; Martínez C; Mascaró JM
Arch Dermatol; 2008 Sep; 144(9):1106-9. PubMed ID: 18794453
[No Abstract] [Full Text] [Related]
8. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
9. Sclerodermatous chronic graft-versus-host disease--a report of four pediatric cases.
Tolland JP; Devereux C; Jones FC; Bingham EA
Pediatr Dermatol; 2008; 25(2):240-4. PubMed ID: 18429789
[TBL] [Abstract][Full Text] [Related]
10. A Pediatric Case of Sclerodermatous Graft-Versus-Host Disease Responsive to Ultraviolet A1 Phototherapy.
Lazzeri L; Tripo L; Pescitelli L; Ricceri F; Prignano F
Pediatr Dermatol; 2016; 33(2):e99-102. PubMed ID: 26871550
[TBL] [Abstract][Full Text] [Related]
11. [Sclerodermatous cutaneous reaction of graft vs host disease treated with thalidomide].
Pédailles S; Troussard X; Launay V; Bazin A; Sentias C; Surbled M
Presse Med; 1993 Jan 2-16; 22(1):37. PubMed ID: 8469665
[No Abstract] [Full Text] [Related]
12. A call for more dermatologic input into chronic graft-vs-host disease clinical trials.
Cowen EW
Arch Dermatol; 2009 Mar; 145(3):337-8. PubMed ID: 19289778
[No Abstract] [Full Text] [Related]
13. Imatinib: A New Tool for the Management of Chronic Sclerodermatous Graft-Vs-Host Disease.
Ferrándiz-Pulido C
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):200-201. PubMed ID: 29429550
[No Abstract] [Full Text] [Related]
14. Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease.
Hurabielle C; Sicre de Fontbrune F; Moins-Teisserenc H; Robin M; Jachiet M; Coman T; Dhedin N; Cassius C; Chasset F; de Masson A; Michonneau D; Bagot M; Bergeron A; Socié G; Peffault de Latour R; Bouaziz JD
Br J Dermatol; 2017 Nov; 177(5):e206-e208. PubMed ID: 28422274
[No Abstract] [Full Text] [Related]
15. Successful treatment of refractory joint contractures caused by sclerodermatous graft versus host disease.
Kim JB; Liakopoulou E; Watson JS
J Plast Reconstr Aesthet Surg; 2008 Oct; 61(10):1235-8. PubMed ID: 17509955
[TBL] [Abstract][Full Text] [Related]
16. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.
Mayer J; Krejcí M; Doubek M; Pospísil Z; Brychtová Y; Tomíska M; Rácil Z
Bone Marrow Transplant; 2005 Apr; 35(7):699-705. PubMed ID: 15696180
[TBL] [Abstract][Full Text] [Related]
17. Koebnerizing sclerodermatous graft-versus-host disease caused by donor lymphocyte infusion and interferon-alpha.
White JM; Devereux S; Pagliuca A; Salisbury JR; du Vivier AW; Creamer D
Br J Dermatol; 2006 Sep; 155(3):621-3. PubMed ID: 16911292
[TBL] [Abstract][Full Text] [Related]
18. Treatment of refractory sclerodermatous chronic graft-versus-host disease with intravenous lidocaine infusions.
Phipps C; Lupo-Stanghellini MT; Flowers ME
Bone Marrow Transplant; 2014 Feb; 49(2):315-6. PubMed ID: 24076547
[No Abstract] [Full Text] [Related]
19. Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients.
Crocchiolo R; Castagna L; El-Cheikh J; Helvig A; Fürst S; Faucher C; Vazquez A; Granata A; Coso D; Bouabdallah R; Blaise D
Exp Hematol; 2011 Sep; 39(9):892-6. PubMed ID: 21703987
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for steroid-refractory chronic graft-versus-host disease.
Cutler C; Miklos D; Kim HT; Treister N; Woo SB; Bienfang D; Klickstein LB; Levin J; Miller K; Reynolds C; Macdonell R; Pasek M; Lee SJ; Ho V; Soiffer R; Antin JH; Ritz J; Alyea E
Blood; 2006 Jul; 108(2):756-62. PubMed ID: 16551963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
